| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Alpha/beta hydrolase domain-containing 6 (ABHD6), also known as α/β-hydrolase domain 6, an enzyme which catalyzes the hydrolysis of 2-arachidonoylglycerol (2-AG). WWL70 is a selective inhibitor of ABHD6 with an IC50 of 70 nM. The compound also inhibits FAAH and MAGL enzymes in mouse brain membrane, with inhibition activities of 102.0%, 95.0%, and 50.0% respectively.
|
|---|---|
| ln Vitro |
When compared to untreated cells, 2-arachidonoylglycerol (2-AG) rose by 20% an hour after WWL70 (10 μM) treatment. WWL70 totally prevented the rise in PGE2 brought on by lipopolysaccharide (LPS) at 1 or 10 μM. WWL70 also decreased the mRNA expression of LPS-enhanced mPGES-1 and mPGES-2. About 100 nM is the IC50 of WWL70, which inhibits PGE2 biosynthesis[2].
WWL70 inhibits ABHD6 with an IC50 of 70 nM, blocking the hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). This results in increased 2-AG levels and modulation of endocannabinoid signaling. In mouse brain membrane, WWL70 also inhibits FAAH (102.0%) and MAGL (95.0%), in addition to its primary target ABHD6 (50.0%). The compound's multifaceted bioactivity makes it a valuable tool for studying the roles of ABHD6, MAGL, and FAAH in endocannabinoid signaling and their potential as therapeutic targets for inflammation, pain, and neurodegenerative diseases. |
| ln Vivo |
Treatment with 10 mg/kg WWL70 considerably improved performance, while post-treatment with 5 mg/kg WWL70 showed little impact. In traumatic brain injury (TBI) mice, WWL70 therapy enhances motor coordination in a concentration-dependent way. The fall latency rose in rats given 5 mg/kg WWL70 on days 3 and 7, respectively, from 74.92±4.8 to 99.57±5.21 (p<0.01) and 87.32±4.42 to 100.14±3.56 (p<0.05). injuries in comparison to the TBI group of vehicles. Beginning on the first day following injury, motor coordination is improved by WWL70 at a therapeutic level of 10 mg/kg. TBI mice treated with WWL70 were able to consistently switch arms throughout Y-maze exploration (69.67±4.98%) [3].
In vivo, WWL70 modulates endocannabinoid signaling by inhibiting ABHD6 and increasing 2-AG levels. The compound has been used in preclinical studies to investigate the role of ABHD6 in various physiological and pathological processes, including inflammation, neuroprotection, and pain. By increasing 2-AG levels, WWL70 may produce anti-inflammatory and neuroprotective effects. However, detailed in vivo efficacy data in specific disease models is more limited and primarily derived from academic research studies. |
| Enzyme Assay |
In vitro enzyme assays for WWL70 involve measuring the inhibition of ABHD6, MAGL, or FAAH enzymatic activity using fluorogenic or radiometric substrates. For ABHD6 inhibition, the enzyme is incubated with a fluorogenic substrate (such as 7-hydroxycoumarin arachidonate) and various concentrations of WWL70. The release of fluorescent product is monitored over time, and IC50 values are determined from concentration-response curves. Similar assays are performed for MAGL and FAAH using appropriate substrates.
|
| Cell Assay |
Cellular assays for WWL70 involve treating cells (such as neurons or microglia) with the compound and measuring changes in 2-AG levels using LC-MS/MS. The compound's effects on endocannabinoid signaling are assessed by measuring downstream signaling events such as activation of cannabinoid receptors (CB1 and CB2) or changes in intracellular calcium levels. These assays confirm that WWL70 increases 2-AG levels by inhibiting ABHD6-mediated hydrolysis, leading to modulation of endocannabinoid signaling.
|
| Animal Protocol |
In vivo animal studies for WWL70 typically involve administration to rodents via intraperitoneal (i.p.) or oral routes. The compound's effects on endocannabinoid levels in brain and peripheral tissues are measured using LC-MS/MS. Behavioral assays are used to assess the compound's effects on pain, inflammation, anxiety, and other endocannabinoid-modulated processes. Pharmacokinetic parameters are determined from serial blood sampling. These studies help elucidate the role of ABHD6 in various physiological and pathological processes.
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies of WWL70 in animal models show that the compound is absorbed following systemic administration and distributes to the brain, where it can inhibit ABHD6 and increase 2-AG levels. The compound's pharmacokinetic profile supports its use as a research tool for studying endocannabinoid signaling. However, detailed pharmacokinetic data (such as half-life, bioavailability, and metabolism) is primarily available from academic research publications rather than comprehensive drug development reports.
|
| Toxicity/Toxicokinetics |
Preclinical toxicity studies of WWL70 are primarily limited to research use, and comprehensive toxicological evaluation for clinical development is not available as the compound is mainly used as a research tool. At concentrations that inhibit ABHD6 (70 nM), the compound is generally well tolerated in cell-based assays. The compound's selectivity for ABHD6 over other related enzymes contributes to its utility as a pharmacological tool for studying the role of ABHD6 in endocannabinoid signaling without significant off-target effects.
|
| References |
|
| Additional Infomation |
WWL70 is a research compound primarily used as a selective pharmacological tool to study the role of ABHD6 in endocannabinoid signaling. The compound has not been developed for clinical use and is not approved for human therapy. It is widely used in academic and pharmaceutical research to investigate the therapeutic potential of ABHD6 inhibition for conditions such as inflammation, pain, and neurodegenerative diseases. WWL70's multifaceted bioactivity (inhibiting FAAH, MAGL, and ABHD6) makes it a useful tool for probing the endocannabinoid system, but its lack of absolute selectivity for ABHD6 over other related enzymes should be considered when interpreting experimental results.
|
| Molecular Formula |
C27H23N3O3
|
|---|---|
| Molecular Weight |
437.48982
|
| Exact Mass |
437.173
|
| CAS # |
947669-91-2
|
| PubChem CID |
17759121
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
653.1±55.0 °C at 760 mmHg
|
| Flash Point |
348.8±31.5 °C
|
| Vapour Pressure |
0.0±2.0 mmHg at 25°C
|
| Index of Refraction |
1.634
|
| LogP |
3.82
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
33
|
| Complexity |
635
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QTWNORFUQILKJL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C27H23N3O3/c1-30(18-19-3-2-4-24(17-19)22-13-15-29-16-14-22)27(32)33-25-11-9-21(10-12-25)20-5-7-23(8-6-20)26(28)31/h2-17H,18H2,1H3,(H2,28,31)
|
| Chemical Name |
4'-carbamoyl-[1,1'-biphenyl]-4-yl methyl(3-(pyridin-4-yl)benzyl)carbamate
|
| Synonyms |
WWL 70 WWL70 WWL-70.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~17.33 mg/mL (~39.61 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (5.71 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.2 mg/mL (5.03 mM) in 5% DMSO + 40% PEG300 + 5% Tween80 + 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2858 mL | 11.4288 mL | 22.8577 mL | |
| 5 mM | 0.4572 mL | 2.2858 mL | 4.5715 mL | |
| 10 mM | 0.2286 mL | 1.1429 mL | 2.2858 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA